Stay updated on Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.9%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check34 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check62 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check69 days agoChange DetectedThe webpage has updated its content to reflect new dates and a scoring system for endoscopic lesions, while removing outdated dates and similar content related to the assessment of response rates.SummaryDifference2%
- Check76 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a clinical trial for Pembrolizumab in treating Recurrent Respiratory Papillomatosis, while adding new collaborators and a revision number.SummaryDifference51%
Stay in the know with updates to Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Respiratory Papilloma Clinical Trial page.